Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
E-pub ahead of print

Influence of mutagenic versus non-mutagenic pre-operative chemotherapy on the immune infiltration of residual breast cancer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Publishing your trial protocols with Acta Oncologica; your contribution to scientific transparency

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. European cancer rehabilitation and survivorship, 2018: one of a kind

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Empty peptide-receptive MHC class I molecules for efficient detection of antigen-specific T cells

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Real-world evidence to guide healthcare policies in oncology

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Correction: Tumour-reactive T cell subsets in the microenvironment of ovarian cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Peptide Super-Agonist Enhances T-Cell Responses to Melanoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Collagen density regulates the activity of tumor-infiltrating T cells

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Anna-Mária Tőkés
  • Orsolya Rusz
  • Gábor Cserni
  • Erika Tóth
  • Gábor Rubovszky
  • Tímea Tőkés
  • Laura Vízkeleti
  • Lilla Reiniger
  • Renáta Kószó
  • Zsuzsanna Kahán
  • Janina Kulka
  • Marco Donia
  • András Vörös
  • Zoltan Szallasi
Vis graf over relationer

Background: Chemotherapeutic agents are often mutagenic. Induction of mutation associated neo-epitopes is one of the mechanisms by which chemotherapy is thought to increase the number of tumor-infiltrating lymphocytes. It is not known, however, whether treatment with various chemotherapeutic agents with different mutagenic capacity induce a significantly different number of stromal tumor-infiltrating lymphocytes (StrTIL) in residual cancer. Methods: One hundred and twenty breast carcinoma cases with residual disease that were treated with one of three types of pre-operative chemotherapy regimens were selected for the study. The percentage of StrTIL was evaluated in pretreatment core biopsies (pre-StrTIL) and post-treatment surgical tumor samples (post-StrTIL). TIL changes (ΔStrTIL) were calculated from the difference between post-StrTIL and pre-StrTIL. Results: When analyzing the pre-StrTIL and post-StrTIL among the three treatment groups, we detected significant StrTIL increase independently of the treatment applied. Based on distant metastases-free survival analysis, both post-StrTIL and ΔStrTIL was found to be independent prognostic factor in HR negative cases. Conclusions: Significant increase of StrTIL in the residual disease was observed in patients treated with the highly (platinum), moderately (cyclophosphamide) and marginally mutagenic chemotherapeutic agents (taxane, anthracycline). Increase in StrTIL in residual cancer compared to pretreatment tumor tissue is associated with improved distant metastasis-free survival in cases with HR negative breast carcinoma.

OriginalsprogEngelsk
TidsskriftActa oncologica (Stockholm, Sweden)
Sider (fra-til)1-9
Antal sider9
ISSN0284-186X
DOI
StatusE-pub ahead of print - 4 jul. 2019

ID: 57730800